AMG 139
DrugFour dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
NCT Number: NCT01258205
The purpose of this study is to assess the safety and tolerability of AMG 139 following multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and in subjects with mild to severe Crohn's disease (CD).
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
QPharm Pty Limited, Herston, Queensland, Australia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Part A - Healthy Subjects:
Part B - Crohn's Subjects:
Exclusion criteria
Parts A - Healthy Subjects:
Part B only - Crohn's Subjects:
Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
Time frame: 36 weeks
Time frame: 36 weeks
AstraZeneca
Industry
A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease, and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03000101
Colitis, Colitis, Ulcerative
Bologna, Italy
View Trial DetailsNCT07697547
Crohn Disease, Crohn's Disease
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT01155362
Crohn Disease, Crohn's Disease
Los Angeles, California, United States
View Trial DetailsNCT04002180
Crohn Disease, Crohn's Disease
Tokyo, Japan
View Trial Details